新科技   新保障   爱领航   正起航

Certain Diabetes Meds May Lower Gout Risk, Too

作者:admin   来源:QiYou  2019-12-22

The study findings were published Jan. 13 in the Annals of Internal Medicine. Brigham and Women's Hospital funded the study. MONDAY, Jan. 13, 2020 -- Medications called SGLT2 inhibitors lower blood sugar in people with type 2 diabetes. And new research suggests these drugs may have an added benefit -- lowering the risk of gout. Compared with people taking another class of diabetes drugs (GLP1 receptor agonists), those taking the SGLT2 drugs had 36% reduced odds of developing gout, the painful condition that usually starts in the foot. "SGLT2s are one of the most effective classes of medications for people with type 2 diabetes, and they might also reduce risk of gout," said study lead author Dr. Michael Fralick, a general internist at the University of Toronto.

SGLT2 inhibitors are a newer class of prescription medicines for use in adults with type 2 diabetes, according to the U.S. Food and Drug Administration. These medications make the kidneys remove sugar from the body through the urine. Drugs in the SGLT2 inhibitor class include canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance) and ertugliflozin (Steglatro).

People with type 2 diabetes often have too much of a substance called uric acid in their blood. Crystals from uric acid can build up in your joints, causing gout, the authors said in background notes.

Gout is a type of arthritis that affects millions of Americans, according to the U.S. National Institute of Arthritis and Musculoskeletal Diseases.

Gout symptoms often first appear in the big toe. Symptoms can include intense joint pain and swelling.

SGLT2 inhibitors aren't without risk. The FDA has required warnings about potential low bone density and an increased risk of fractures for people taking these drugs. The FDA has also found a higher risk of serious infections and lower limb amputations.

Almost 300,000 adults with type 2 diabetes were included in the study. Their average age was 54. All had recently been prescribed an SGLT2 inhibitor, or a GLP1 receptor agonist, drugs from another new class of diabetes medications that include dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta), and semaglutide (Ozempic).

Of the nearly 152,000 adults taking an SGLT2 inhibitor, 636 developed gout. In the almost 144,000 people taking a GLP1, 836 developed gout, the study found.